No Data
Scilex Holding Announces Publication Of Trial Results For SP-102 (SEMDEXA) In PAIN Journal; Focuses On Non-Opioid Pain Management Products For Acute And Chronic Pain
The Phase 3 study results are being published in PAIN Journal, which is the leading journal devoted to pain medicine and research. PAIN is the official journal of the International Association for the
Express News | Scilex Holding Company Announces Publication in Pain Journal Regarding Phase 3 Results of the Pivotal Registration Trial of SP-102 (Semdexa™) in Lumbosacral Radicular Pain (Sciatica)
B.Riley Financial Maintains Scilex Holding(SCLX.US) With Buy Rating, Maintains Target Price $4
B.Riley Financial analyst Mayank Mamtani maintains $Scilex Holding(SCLX.US)$ with a buy rating, and maintains the target price at $4.According to TipRanks data, the analyst has a success rate of 25.4%
Some Scilex Holding Company (NASDAQ:SCLX) Analysts Just Made A Major Cut To Next Year's Estimates
The analysts covering Scilex Holding Company (NASDAQ:SCLX) delivered a dose of negativity to shareholders today, by making a substantial revision to their statutory forecasts for this year. Both rev
Scilex Holding Initiated at Buy by Rodman & Renshaw
Scilex Holding Initiated at Buy by Rodman & Renshaw
Rodman & Renshaw Initiates Coverage On Scilex Holding With Buy Rating, Announces Price Target of $13
Rodman & Renshaw analyst Brandon Folkes initiates coverage on Scilex Holding (NASDAQ:SCLX) with a Buy rating and announces Price Target of $13.